Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)

Organon and Co1,682 enrolled

Overview

This non-interventional longitudinal study is a follow-up of the Austrian Cholesterol Screening and Treatment project (ACT I), which assessed the cholesterol status, including achievement of the target levels applicable at that time (LDL levels \<100 mg/dL), in participants with coronary heart disease (CHD) already being treated with a statin. In this study, participants without adequate LDL-cholesterol reduction with a statin underwent extension of therapy with ezetimibe with the goal of achieving target levels.

Study Type

OBSERVATIONAL

Enrollment

1,682

Conditions

Hypercholesterolemia

Interventions

EzetimibeDRUG

Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion criteria: * Participants in whom LDL-cholesterol target levels have not been achieved. * Participants in whom a decision has been made by the physician to initiate treatment with ezetimibe (longitudinal analyses). The treatment decision will be made prior to and independent from inclusion of participants into this study. \- Participants with LDL cholesterol levels ≤113 mg/dl and a very high risk, which led to case-by-case approval of medication may be documented. Exclusion criteria: * Any condition which, in the opinion of the treating physician, precludes treatment with ezetimibe. * In order not to interfere with data collection it is recommended not to include participants currently in a clinical trial. * Previous and ongoing treatment with ezetimibe.

Outcomes

Primary Outcomes

Number of Participants Achieving Individual LDL Cholesterol (LDL-C) Target Level

Individual LDL-C target values were set according to the Austrian Cholesterol Consensus (ACC) 2007 for patients for patients suffering from coronary heart disease (CHD) or CHD equivalent in an office-based, routine medical care setting. Participants were categorized as either high-risk or very high-risk based on ACC criteria. The LDL-C target levels for each category were 100 mg/dL and 70 mg/dL, respectively

Time frame: Up to 12 months

Secondary Outcomes

Change From Baseline in Total Cholesterol (TC) at Month 3

Time frame: Baseline and Month 3

Change From Baseline in TC at Month 12

Time frame: Baseline and Month 12

Change From Baseline in LDL-C at Month 3

Time frame: Baseline and Month 3

Change From Baseline in LDL-C at Month 12

Time frame: Baseline and Month 12

Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Month 3

Time frame: Baseline and Month 3

Change From Baseline in HDL-C at Month 12

Time frame: Baseline and Month 12

Change From Baseline in Triglycerides (TG) at Month 3

Time frame: Baseline and Month 3

Change From Baseline in TG at Month 12

Time frame: Baseline and Month 12